A 16 Week Randomized Controlled Trial of the Effect of Aripiprazole Versus Standard of Care on Rates of Non-HDL Cholesterol Among Schizophrenia and Bipolar Patients With Pre-Existing Metabolic Syndrome.
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2013
At a glance
- Drugs Aripiprazole; Olanzapine; Quetiapine; Risperidone
- Indications Bipolar I disorders; Schizoaffective disorder; Schizophrenia
- Focus Pharmacodynamics
- Acronyms OPT
- Sponsors Bristol-Myers Squibb
- 10 Jun 2017 Biomarkers information updated
- 29 Nov 2013 Last checked against ClinicalTrials.gov record.
- 21 Jun 2010 Actual patient number (28) added as reported by ClinicalTrials.gov.